Advertisements
Feeds:
Posts
Comments

Archive for the ‘IP Valuation Models – Pricing Intangible Assets’ Category


In-House Development of an intellectual property value calculator (IP-V-Cal) for Valuation of INTANGIBLE products: Intellectual property (IP) assets of Digital Printed Products (DPP) – Online Journal(s), e-Books and a Corpus of Real Time generated eProceedings of the Top Biotech Global Conferences

Author: Aviva Lev-Ari, PhD, RN

1. All the points I made, below in my e-mail 4AM on 6/28/2019, see below – to match Intangible Assets in Document #2, 4/19/2019 in Inbox of each FIT member.

(after reading Rick’s article we received a link to and after reading the link that I provided in this e-mail)

2. We Need Amnon to enter into an Excel spread sheet as Column #1 all the Contributing Factors to valuation in that 4AM e-mail

3. Columns #2,#3,#4 will be Gail, Amnon, Rick (Business Team)

4. Columns #5,#6 will be Dr. Williams, Prof. Feldman (our Board)

5. Columns #7,#8 #9,#10 will be Dr. Pearlman, Dr. Dror Nir, Dr. Saha, Dr. Irina (Scientists Team)

7. Each Column dedicated to each of out 10 alive and well Active FIT

Will be split into two columns

6. Column #11 will be Aviva’s 

8. First column of each of the 10 FIT members will be filled by each by a number between 50 to 100, representing the subjectively perceived contributing weight of the Factor mentioned in Column 1: list of factors contributing to Venture’s valuation

9. Second column of each of the 10 FIT members will list the member’s subjective perspective on Ranking the Factors in Column #1

10. To Column #1: each Business Team member (mentioned in 3, above), needs to contribute FIVE new factors taken from your discussion on Valuation add them with your initials to Column #1

11. Aviva will bring DATA from Article Scoring System already populating a database designed to quantify the 

11.1 Valuation of the Journal

11.2 Valuation of the BioMed e-Series: each book, each series, all 16 volumes

11.3 Author’s factor in pricing 11.1 and 11.2

 

12. Valuation of 70 eProceedings 

(60 by Aviva; 10 by Dr. Williams)

needs to be tied to a growth factor in LPBI Group’s INFLUENCE on Twitter

12.1 @pharma_BI

12.2 @AVIVA1950

12.3 Gail’s Twitter account

12.4 Dr. Williams’ Twitter account

12.5 Dr. Asha’s Twitter account

12.6 Dr. Irina’s Twitter account

Factors of INFLUENCE:

– Growth in #Followers on Twitter 

– Ratio #Tweets/#Likes

– Cumulative # of Followers’ Followers

13. LinkedIn

I discovered new features and I wish to conduct a Skype training session with narrow messaging to FIT members

Please contribute your thoughts, while 

 

– Amnon is building this Excel

– Irina will be designing DropBox for this Excel that TEN FIT members need to add a number 50 to 100, Ranking the relative importance of each factor for Venture Valuation

GREAT initiative by Business Team to focus on valuation, thank you.

Thank you all FIT members, get ready yo add your subjective numbers into the Valuation Excel.

Amnon, please share with me in a Skype session the draft of this Excel, before we deplore this instrument, place it in Dropbox and announce the window of one week when we collect 2×10 data points on each of the Factors in Column #1, 

Board members and Scientists: you are welcome to contribute Factors in Valuation of the Venture in Column #1, the longer this column, the greater the granularity. 

We can then focus only on factors that scored above the Mean or any cut off point we will agree upon.

Thank you all – it is exciting to get the entire Team, developing a custom tailor methodology for DIGITAL printed products, NO OFF THE SHELF MODEL WILL FIT US. 

Current valuation models that do NOT APPLY to our venture include the following:

“Book to market value” 

– we got Intangibles, Column #1

– LPBI Group’s Tangibles are royalties for books sold. 

(all data was reviewed by Dr. Williams, for Section #13 in Document #2, for the period, 4/2012 to 4/19/2019)

“VC investment dilution models” 

– we kept 100% of ownership 

– our shareholders are 12 FIT members: 

— >>>>>> 10 are active members 

– (Scientist Team: Formula in place) (Gail included)

– (Business Team: 10% of UPSIDE) (Gail included)

— >>>>>> Past commitments outstanding:

– to Dr. Larry and 

– to Adam Sonnenberg

– (Formula in place). 

– No UPSIDE, due to idle status since 2/6/2019, Exit period launch.

Thank you again.

Aviva Lev-Ari, PhD, RN

Editor-in-Chief, BioMed e-Series

http://PharmaceuticalIntelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

On Jun 28, 2019, at 3:57 AM, Amnon Danzig <amnon.danzig@gmail.com> wrote:

This is a nice article that put in place Corporate Finance practices.

However, The Business Team currently is struggling in much more earlier stages of the valuation of the Group.

We have a long way to go before we are entering the valuation scene in numeric terms.

Aviva,

I must confess that in the last two weeks we (Rick, Gail and me) invested huge amount of work to disclose the real valuation of the Group.

It is a work-in-process.

Thank you for your patience.

Amnon

Amnon Danzig

Business Strategy 

https://lnkd.in/e-zTVz4

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Israel

http://pharmaceuticalintelligence.com 

e-Mailamnon.danzig@gmail.com

(M) +972-54-6998405

 www.amnondanzig.com

SkypeID: Amnon.Danzig  LinkedIn Profile Twitter Profile

On Fri, Jun 28, 2019 at 10:30 AM Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

What is Aviva’s take on LPBI Group Valuation?

https://bothsidesofthetable.com/do-you-really-even-need-vc-72013e985fab

  • Advantages of LPBI Group:
  1. We had low barrier to entry and 
  2. We had/have Zero labor cost
  3. We are virtual, therefore, no overhead expenses 
  4. Run rate at WordPress.com Business Premium Annual Fee $200 and LinkedIn Annual Business Premium $1000
  5. Our 1st CARDINAL factor of production [The Team] is the DEAPTH and very diverse EXPERTISE residing in the Scientist Team and in the Business TEAM
  6. Leadership expressed by new timely challenge selection – Directions into new domains
  7. Team ability to swarm around new domains (new timely challenge selection), Examples: 
  • 2015-2016 – 3D BioPrinting – Book: Series E, Volume 4
  • Volume 4: Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices. On Amazon.com since since 12/30/2017

https://www.amazon.com/dp/B078QVDV2W

  • 2016-2017 – Drug Discovery – JV with SBH Sciences, Dr. Raphael Nir

https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/

  • 2019-2020 – AI + ML in Medicine – Book: Series B, Volume 2

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

  1. Our 2nd CARDINAL factor of Leadership is the FIDELITY of a CORE team of Scientists
  2. Aviva’s ability to multitask on several levels – FIVE persons in just One woman (nee: 1950): 
  • LPBI Group’s DAILY activity on Twitter, LinkedIn, Facebook
  • IN PERSON at +60 Conferences – yielded a Corpus of eProceedings N=70 [10 by Dr. Williams 
  • Curator of new content – Journal is LIVE at 

1,639,029 eReaders 

Content

5,642

Posts

686

Categories

10,083

Tags

  • Book Editor – multiple domains of knowledge: Series A, B, D, E
  • Full functions of Editor-in-Chief: 16 Titles, content acquisition, eTOCs designer
  • Relations builder with multiple Ecosystems: Israel, US, Europe – stay tune

4/19/2019 

@pharma_Bi # Followers = 505 

6/28/2019

@pharma_Bi # Followers = 519 RatioTweets to Likes: 25,000/3,086

4/19/2019 

@AVIVA1950 # Followers = 359

6/28/2019

@AVIVA1950 # Followers = 439 RatioTweets to Likes: 11,000/5,615

How can you use all of the above for your Valuation Modeling???

Advertisements

Read Full Post »